Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
pennyrobin, I have no doubt they do. I just hate weeks like this is all when you know something is coming soon, nothing is happening and all you can do is wait and feel helpless. LOL.. kind of like Christmas waiting for Santa to arrive.
Boring like watching paint dry.
I think someone mentioned that before, and lately it sure seems that way. No action what so ever, no news, no website updates, nothing.
Almost like watching a B-flick movie, waiting for something, anything to happen of substance.
I wonder if I am actually sleeping waiting for POSC information to spring forth.
I see this type of posting from a company when they are actually doing solicitataion to usually get others to buy in a report of what you already know the information about.
I also like how it held up nicely when the market was being slaughtered before.
I too think it is more news driven then how the chart may reflect it for larger cap stocks. It has been a little while since any real news has come out on this company. I think the news that needs to come out to actually make this move is either a partnership announcement with the NYSE company that was touted before, or that they actually shown on paper the orders that have been mentioned with a delivery date.
If we can also break back into the .15 and higher, than I think this stock will have alot more interest to others as well.
davidio, I can not find that information on NASDAQ or any other site. Can you please post us the link you found the POSC Smart Scan Chart Analysis was done on. Thanks!
It is not illegal to post any emails sent to the public. If it was interoffice email you were posting, then yes you would be correct. But an email to someone in the public, even shareholder, you are ok.
But if you work at their company, or the company they would be working with, then yes you can not list any of it here or anyplace else without commiting a violation.
davidio, Total of listed is -20, not -60.
-25 + -20 + -15 = -60
+10 + +30 = 40
-60 + +40 = -20
barbershop, as a side note on commments, you have 15 minutes to perform editing your comment once it is made. Just access the comment as if you are reading it and then click on the edit msg link to make changes on the posting.
123thisisme, I see no author to the story. I see it also coming from a site that I have always questioned on being complete, truthful and unselfserving. Whoever this unknown, unlisted author is, appears what they are trying to represent as factual is not reflecting a whole story, outdated information, picking pieces from here and there from places in their mind or the web, etc, and trying to make it fit together for a quick school report.
It would not surprise me if this unknown author was whomever the person was that was trying to stir up trouble here on this board a couple of weeks ago.
In otherwords, I would not put any faith into what this unknown, unauthoring person is trying to say in the article. Sad to see this fiction on the web, but it is open to everyone who wants to try their hand at being a real journalist. There are a lot better news reporing sites that are accurate and factual.
GLTA
Here is the complete article from AuntMinnie, as I am not a member so I can not see it through the prior comment link. I attached the link to the article I got through Google, which is the only way I was able to see the full article.
http://www.auntminnie.com/index.asp?sec=ser&sub=def&pag=dis&ItemID=84764
Positron places bets on PET-only Attrius system
By Wayne Forrest
AuntMinnie.com staff writer
March 4, 2009
Positron has had its ups and downs, to say the least, over the past decade, but the PET device developer thinks it now has a strategy and product to become a more prominent player in the nuclear medicine market.
Fishers, IN-based Positron is banking on the appeal of Attrius, its PET-only device designed for cardiac imaging at community and rural hospitals as well as cardiology practices.
Positron's Attrius cardiac PET scanner. Image courtesy of Positron.
Attrius and the novel strategy behind it are the brainchild of Positron president Joseph Oliverio and medical director Dr. Michael Merhige. Merhige came from a cardiac group in Buffalo, NY, which began using cardiac PET imaging in an outpatient setting in 1995, around the time Medicare began to reimburse for such scans.
In 2003, the pair was recruited by a community hospital in Niagara County, NY, which had one of the worst coronary disease death rates per county in the U.S. Like many community hospitals in the country, the facility had a difficult time competing against larger tertiary care centers, Oliverio said, and didn't have a unique cardiovascular offering to stop the migration of patients to other facilities, or to attract patients from other hospitals.
With the help of cardiac PET, the facility was successful in reducing the heart attack and cardiac death rate in the county, as well as the number of angiograms that were being performed, by providing a more accurate diagnosis of cardiac disease through PET, Oliverio said.
Bucking the PET/CT wave
Oliverio acknowledges that the strategy bucks the popularity of PET/CT systems among healthcare facilities. A recent report by market research firm IMV Medical Information Division of Des Plaines, IL, found that no PET-only scanners were installed in the U.S. in 2008; PET-only devices made up 3% of the total installed in 2007 and 60% of systems installed in 2001.
"Everything is going PET/CT, but I didn't see the value in having a combination PET/CT device for cardiovascular use," he said. "There is the benefit of a CT angiogram with PET perfusion, but I am not buying the argument that it needs to be in the same setting. I understand with oncology there is a great benefit in having the patient on the same [PET/CT] table, but with cardiovascular imaging, I didn't see the economic benefit or the clinical benefit."
So, with the expiration of some patents, Positron set out to design and manufacture a less expensive PET-only camera for the community hospital and cardiologist office market. The first key step was to partner with Neusoft Medical Systems of Shenyang, China, starting in January 2006, to begin the manufacture of a PET-only system.
Positron submitted its 510(k) clearance application for Attrius to the U.S. Food and Drug Administration (FDA) in January. Once cleared, the company could begin marketing the device in the U.S. this year.
Oliverio said the Neusoft Positron Medical Systems joint venture could produce as many as 50 PET-only systems per month, if necessary. Positron has exclusive marketing rights for Attrius in the U.S., while Neusoft has exclusivity in China. The two companies share marketing rights in the rest of the world.
Price point
Oliverio did not offer a specific price for Attrius, other than to say it is "priced significantly less than cardiologists' choices for new PET/CT scanners."
The device offers a coronary disease quantitative software package written by cardiac PET pioneer Dr. K. Lance Gould from the University of Texas Medical School at Houston. In addition, Positron plans to offer ejection fraction analysis and CT angiography fusion with PET data through third-party software.
Oliverio is optimistic that Attrius will be well received by healthcare providers looking for a cardiology niche. "We know that the cardiac PET market is expanding, primarily because we see large and mid-sized pharmaceutical companies trying to develop a single-dose F-18-based cardiac perfusion agent," he said. "They wouldn't be developing it if they didn't feel the market wasn't going to flourish."
Positron also has been in contact with Bracco Diagnostics of Princeton, NJ, which markets the PET radiopharmaceutical CardioGen-82 (rubidium Rb 82 generator), the only generator-based PET cardiac perfusion agent approved by the FDA and reimbursed for coronary artery disease evaluation.
"We have been in close contact with them and they have reassured us that there is a significant demand for [a PET-only cardiac system]," Oliverio said.
PET's efficacy
Previous research also would appear to support the efficacy of cardiac PET. Researchers from the State University of New York at Buffalo, led by Merhige, found that the use of PET myocardial perfusion imaging with rubidium-82 in patients with intermediate coronary artery disease resulted in a greater than 50% reduction in invasive coronary arteriography and coronary artery bypass graft surgery.
Merhige, who also serves as director of the Heart Center of Niagara in Niagara Falls, NY, and colleagues also wrote that there was a 30% cost savings by avoiding additional procedures, and patients experienced "excellent clinical outcomes at one year compared with SPECT" (Journal of Nuclear Medicine , July 2007, Vol. 48:7, pp. 1069-1076).
Marketing strategy
Positron currently is establishing marketing and distribution channels, with cardiology offices as "the primary target," Oliverio said. "However, I believe the largest societal benefit of this technology will be through placing these systems within the rural hospital market."
Positron also created a program called PosiRx to give imaging providers the choice of radiopharmaceuticals, dispensing systems, molecular imaging devices, and equipment service directly from the company. Positron will offer distribution and dose dispensing of radiopharmaceuticals through its Nuclear Pharm-Assist device.
With the U.S. economy currently in dire straits, limiting the ability of many hospitals to pursue new capital equipment purchases, Positron also is looking to partner with a financing company to stimulate the PET market.
"With cardiac PET, it is known that it will have a clinical benefit if it is put into practice," Oliverio said. "At the same time, the ability to monitor therapy and take advantage of the trends of medicine going toward proactive, nonsurgical methods, and the ability to track coronary disease progression, reversal, or cessation of disease, is priceless, in my opinion."
By Wayne Forrest
AuntMinnie.com staff writer
March 4, 2009
Related Reading
Neusoft Positron files 510(k) for Attrius, January 29, 2009
Positron launches cardiac nuclear medicine package, January 9, 2009
Positron hires medical director, December 17, 2008
Neusoft taps TUV for FDA help, October 23, 2007
Positron opens Chinese joint venture, February 13, 2006
Copyright © 2009 AuntMinnie.com
Last updated np 3/3/2009 12:44:16 PM
dblue, I also had originally bought in the high end about .24 and .27 when I first got into this company stock. Since then I have been able to invest more and average it out to .176 I think it is now. I was able to load up alot into the .114 range or something very close to that to make me average down alot.
I also feel very good for this company in the next month to two months, and even as long as out to 12 months I see this doing extremely well.
I feel the same way as you here dblue.
dblue, if you do not care, then I guess you are saying it may as well head to .01, and I am sure you were not trying to say that as well.
I was not trying to say it is something we should fear, and I am sure you were meaning the same thing, but saying 'who cares' makes me feel that you are ok in seeing it hit pre .05 levels and maybe even .009.
I was just trying to express my thoughts on how today probably would go. Some of us do like to see a rise, even if small. We all know that things fall back, which is why I thought it was benifical to buy into more earlier as I stated I did.
You may be in it for years, but I don't think everyone is (I know I can not be for financial reasons at least not now), some maybe days for any day traders as this seems to be a good one in how it fluxuates, and some maybe for just a short 2 to 6 months.
Again I was not trying to bash or anything like, just expressing my outlook for today in case anyone was maybe holding off and trying to get in lower.
Since we have declined and flattened since 10:30 AM, I am expecting that we will decline even further today as for myself I see no momentum to push this back up. I can only see it falling if someone tries to sell of their shares at end of day. I hope I am wrong, but just how I am looking at end of day being.
What does GETG have to do with POSC?
Another 29K added in this morning. .133 and .141
Interesting price differences on my two different brokers for this stock.
One shows bid/ask price as .146/.155 while the other one shows .139/.19.
Could be an interesting day today.
Covidien to Present at Bank_of_America Merrill_Lynch Conference
Here is more information on what ventrikel posted about. It may be beneficial in listening as they may say something about Positron, and if they do I think we would like to know about it at the same time the market hears it. I am not trying to imply they will, but some on here believe they may be the company to be annouced soon.
http://investor.covidien.com/phoenix.zhtml?c=207592&p=irol-newsArticle&id=1424001
Covidien to Present at Bank of America Merrill Lynch Conference
MANSFIELD, Mass., May 07, 2010 (BUSINESS WIRE) --Covidien (NYSE: COV), a leading global provider of healthcare products, will present at the Bank of America Merrill Lynch 2010 Health Care Conference in New York on Thursday, May 13, 2010. José (Joe) Almeida, President, Medical Devices, will represent the company in a session scheduled at 8:00 a.m. ET.
A live audio webcast of the presentation can be accessed at Covidien's Investor Relations website: http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Finvestor.covidien.com&esheet=6280534&lan=en_US&anchor=http%3A%2F%2Finvestor.covidien.com&index=1&md5=354e9a4f99b97175e8dcd38439b27572. An archived edition of the presentation will be available following the live webcast.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2009 revenue of $10.7 billion, Covidien has 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.covidien.com&esheet=6280534&lan=en_US&anchor=www.covidien.com&index=2&md5=2df39d284b6be13a335ab0f83c6f27f3 to learn more about our business.
SOURCE: Covidien
Covidien
Eric Kraus, 508-261-8305
Senior Vice President
Corporate Communications
eric.kraus@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com
or
Brian Nameth, 508-452-4363
Director
Investor Relations
brian.nameth@covidien.com
Hi var, I would tend to agree with you, but I am just being cautious on timeline as he slipped in at the last moment two words of 'or so' after saying month (singular). That made me think that he is not real sure when it will happen but sounds like he hopes it happens in a couple of weeks to a month.
Hopefully sooner than later.
OK. It would be nice to have it by the end of this month, even better if we can have it next week.
I am stacked very tall and long on this one.
Did Rooney follow up since MarketSite to say it will be by end of month?
As I understood him, it could happen in as little as two weeks to possiblly months in how he chose his words.
Snippet from the MarketSite transcript:
UNIDENTIFIED PARTICIPANT: One other quick question as it relates to partnerships and joint ventures, et cetera that you were discussing earlier. Is there anything that we should be looking for – to over the upcoming weeks or months in that regard or can you talk about that?
ROONEY: Yes, the next few weeks to a month or so we will have more information on certain alliances that we have. And we'll keep you posted.
I agree .15 would be nice.
As it is sitting right now, if we can not get back to above .15, and stay where we are currently at through about 3 PM, then I think we will see this falling possibly into negative territory today.
Billy, The last paragraph you posted is the one I posted earlier making me think that the comment on "This multi-billion dollar corporation pushing cardiac PET and that will certainly only benefit Positron Corporation." Where "This" is referring to Lantheus in how I am reading the transcript since no other company was mentioned.
Your later post from the company cleared that up. Thanks again.
Thanks, Billy, for everything (eom)
Guy, I could not find anything either. This is the closest I could find of anything of interest to me at first.
http://www.reuters.com/article/idUSN0456726420100504
New Issue-Lantheus Medical sells $250 mln notes
Tue May 4, 2010 3:47pm EDT
May 4 (Reuters) - Lantheus Medical Imaging Inc on Tuesday sold $250 million of senior notes in the 144a private placement market, said IFR, a Thomson Reuters service. The size of the deal was increased from an originally planned $225 million. Jefferies was the sole bookrunning manager for the sale.
BORROWER: LANTHEUS MEDICAL IMAGING INC
AMT $250 MLN......COUPON 9.75 PCT.....MATURITY 5/15/2017
TYPE SR NOTES.....ISS PRICE 100.......FIRST PAY 11/15/2010
MOODY'S B2........YIELD 9.75 PCT......SETTLEMENT 5/10/2010
S&P B-PLUS........SPREAD 674 BPS......PAY FREQ SEMI-ANNUAL
FITCH N/A.........MORE THAN TREAS.....NON-CALLABLE 4 YRS*
*MAKE-WHOLE-CALL 50 BPS
gqguy, To be honest I am not sure who it may be, but I just found it interesting that both items (Lantheus investing in cardiac PET specifically, and This multi-billion dollar corporation) were mentioned in the same paragraph.
Also to add I am not sure if Lantheus is even traded or not. I guess I should have looked more into that, but I wanted to point out what I thought was staring me in the face.
JJ, Sorry I do not understand your ($25) multi-billion corporation comment about the article.
Can you please restate? Thanks
Posted by: JJSeabrook Date: Tuesday, May 11, 2010 9:16:25 PM
In reply to: crammerfool who wrote msg# 3936 Post # of 3937
I agree, crammer, but in Pennyland if you tout a $25B corporation as a partner and only give them a multi-billion Dollar Corporation as a partner, they feel cheated! LMAO
The Multi-Billion dollar corporation....
This sounds to me as if they are saying who the company is that they will be partnering with based upon the PR from several weeks ago and the MarketSite 8K report both saying the same thing. But here they give that (partnership) company a name in my opinion.
Lantheus took SPECT imaging from 1,000 to 2,000 to 7 million procedures done currently per year. They have divested their interest from SPECT and are investing in cardiac PET specifically, a cardiac PET drug that performs well on our scanner. So we expect not only Positron as a driving force but Lantheus as well. This multi-billion dollar corporation pushing cardiac PET and that will certainly only benefit Positron Corporation.
Lantheus information:
http://www.lantheus.com/Pipeline.html
Thanks Blondie (eom)
Here is a link to the SEC in case you wish to search for information:
http://www.sec.gov/edgar/searchedgar/companysearch.html
Didn't someone say yesterday that today it would dip in the morning until about 10:15 am and then run up after that?
Not the video but something you can read.
http://www.foxbusiness.com/story/markets/industries/health-care/positron-showcased-nasdaq-marketsite/
Thursday, May 06, 2010
Positron Showcased at NASDAQ Marketsite
Comtex INDIANAPOLIS, May 06, 2010 (BUSINESS WIRE) ----Positron Corporation (OTCBB:POSC) (the "Company") a molecular imaging solutions company focused on Nuclear Cardiology, announced the highlights from the Company's presentation before NASDAQ on May 5, 2010.
The Management of Positron Corporation introduced the Company at the NASDAQ Marketsite. This forum is of great value to Positron since it provides broad exposure and access to a far reaching investment community.
The Company set out to explain the foundation of its business, the confirmation of a strategic partnership and potential revenue. Management discussed most all aspects of the Company's plans which it was at liberty to disclose. A transcript of the presentation will be filed with the Securities and Exchange Commission on a Form 8-K immediately when it becomes available in coming days.
Positron representatives did confirm an agreement with an industry leading strategic partner that will give the Company the ability to greatly expand the Company's revenue stream and our position in the molecular imaging market by offering imaging systems and radiopharmaceutical distribution. Patrick Rooney, Positron Corporation's CEO states, "We would have liked to introduce a certain synergistic business partner as was stated in the press; however it was the recommendation of both companies to not disclose further details due to a potential expansion relationship and certain strategic competitive advantages. We anticipate additional information will be disclosed in the near future."
Positron also gave guidance as to its target revenue. Based on the Company's research and unique positioning in the marketplace, Positron projects significant sales growth quarter over quarter, year over year. Positron projects that in the next 5 years the nuclear cardiology market will approach $1.5 Billion in revenue annually. The projections reflected sales from Positron's PET device and radiopharmaceutical devices and services. Positron may potentially achieve greater revenue as it expands into new markets with broader indications that we expect will be fully supported by Medicare and private payers.
About Positron: Positron founded in 1983, is a molecular imaging company focused on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging systems to radiopharmaceutical distribution. Positron products include: the Attrius(TM), a PET imaging device; the Pulse(R), a SPECT imaging device; the Nuclear Pharm-Assist(R), an automated radiopharmaceutical distribution device; and the Tech-Assist(TM), a radiopharmaceutical injection shield. Positron is headquartered in Indianapolis, Indiana. More information about Positron is available at www.positron.com.
Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (317) 576-0183.
SOURCE: Positron Corporation
Positron Corporation
Patrick Rooney
(317) 576-0183
Copyright Business Wire 2010
I believe that the trade that was posted in AH was an accumlation of trades that took place over time and they are posting the average price for all shares. If I remember right, I noticed that it is posted as a trade to the Asking price, so a Buy from someone investing.
Many 100,000 & 200,000 trades occuring at .14
I see more buying into the Ask then I see selling into the Bid.
If we can hold the .145 and push up at end wound be great to be over .15 today.
Hoping this breaks .20 as my other stock is .06 away now from breaking 2.00. Would love to see them both go over on the same day.
I think if you have not bought now, then you are probably waiting too long to get back in.
I hope so, otherwise I think we will see this around .13 today as it is going. But I hope it closes up more where I mentioned earlier.
Hopefully .15 can be held through closing today.
If it drops lower than I think we are going to lose more ground.
Would be nice to see this actually close about .165/.17
Update: Guess i spoke to late. See it dipping before .15 now